Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.

 Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J.
J Neural Transm 1985;64(2):113-27 

Abstract

In an open, uncontrolled study the longterm (9 years) effect of treatment with Madopar alone (n = 377) or in combination with l-deprenyl (selegiline, selective monoamine oxidase type B inhibitor) (n = 564) have been compared in Parkinsonian patients. In patients who lost their response to conventional Madopar therapy the addition of l-deprenyl resulted in a significant recouping of levodopa effect. The survival analysis revealed a significant increase of life expectancy in Madopar--l-deprenyl group regardless of the fact whether or not the significant demographic differences between the two groups were taken into account. Although the mechanism underlying this action of l-deprenyl is not known, the results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons. l-Deprenyl is the first anti-Parkinson drug having such a property. This hypothesis is not far fetched since l-deprenyl selectively prevents the degeneration of striatal dopaminergic neurons induced in animals by the illicit drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Since latter compound is known to cause Parkinsonism in man and primates or Parkinson-like neurochemical and pathological changes in other animals the implications of the present study involving monoamine oxidase activity and l-deprenyl are apparent.
Deprenyl   improves depression

Deprenyl   is an effective antidepressant

Deprenyl   in treatment-resistant older depressive patients

Deprenyl   + phenylalanine was beneficial in 90% of depression patients

Deprenyl   antidepressant effects are by means other than MAO-B inhibition

Deprenyl   treated rats were much more sexually active

Deprenyl   enhances sexual performance and longevity in rats

Deprenyl   may delay the deterioration of neurons during aging

Deprenyl   the history of deprenyl

Deprenyl   decreases susceptibility to Parkinson's & Alzheimer's disease

Deprenyl   restores IGF-1 to youthful levels

Deprenyl   protects the vascular endothelium from beta amyloid plaque

Deprenyl   reduces cocaine "high"

Deprenyl   prolongs animal lifespan by reducing oxidative damage to the brain

Deprenyl   may be useful in the treatment of cocaine dependence

Deprenyl   increases the life span in Fischer rats

Deprenyl   effects on short term memory in young and aged dogs

Deprenyl   maintains sexual acitivity in old rats

Deprenyl   and Fluoxetine (Prozac) do not interact in combination

Deprenyl   prolongs life in elderly dogs

Deprenyl   has a cardiac neuroprotective effect

Deprenyl   reduces oxidative stress and increases free radical elimination

Deprenyl   responses of forebrain neurons to deprenyl

Deprenyl   Parkinson's and Alzheimer's patients need 10 mg of deprenyl daily

Deprenyl   inhibits tumor growth in rats with mammary tumors

Deprenyl   slows the decline of sexual and learning performances in rats

Deprenyl   is ten times stronger than methamphetamine as a catecholaminergic

Deprenyl   shows favorable results in Tourette's syndrome and narcolepsy

Deprenyl   treated rats lived beyond the known maximum lifespan

Deprenyl   protects cells from the DNA damage

Deprenyl   may protect neurons from ischemic or oxidative damage

Deprenyl   prolongs animal lifespan by reducing oxidative damage to the brain

Deprenyl   effects on cocaine-induced euphoria

Deprenyl   effects on response to experimental cocaine administration  

Deprenyl   Are metabolites of deprenyl useful or harmful?

Deprenyl   slows the progression of Parkinson's disease

Deprenyl   suppresses excitotoxic damage in Parkinson's disease

Deprenyl   effect of deprenyl on arm movement in early Parkinson's

Deprenyl   effect on cognitive functions in early Parkinson's 

Deprenyl   prolongs the life span of Parkinsonian patients significantly

Deprenyl   depression in Parkinson's disease

Deprenyl   increases the dopamine content of the nerve terminals in Parkinson's

Deprenyl   improves visuo-motor control in early Parkinsonism

Deprenyl   management of early Parkinson's disease

Deprenyl   delays the onset of disability in Parkinsonian patients

Deprenyl   and tocopherol antioxidative therapy of Parkinsonism

Deprenyl   slows the death of nigral neurons in Parkinson's disease

Deprenyl   + levodopa treated Parkinson's patients live longer

Deprenyl   stimulates biosynthesis of cytokines interleukin-1 & 6

Deprenyl   effect of MAO-B inhibitors on MPP+ toxicity

Deprenyl   modulates the activity of catecholamine-sensitive neurons

Deprenyl   improves the performance of patients with Alzheimer's disease

Deprenyl   for Alzheimer's disease  

Deprenyl   MAO-B inhibitors in the treatment of Alzheimer's disease

Deprenyl   in the treatment of Alzheimer's disease

Deprenyl   stimulates biosynthesis of cytokines interleukin-1 & 6

Deprenyl   and age-related decline of the striatal dopaminergic system

Deprenyl   increases dopamine in the striatum of primates

Deprenyl   use in treatment-resistant elderly depression patients

Deprenyl   protects against neurotoxins

Deprenyl   increased rat lifespan by 5%

Deprenyl   pharmacology

Deprenyl   is an MAO-B inhibitor

Deprenyl   facilitates neuronal growth without inhibiting monoamine oxidase

Deprenyl   and levodopa in Parkinson's disease

Deprenyl   pharmacology

Deprenyl   biochemical actions

Deprenyl   increases life span in Parkinson's patients

Deprenyl   the history of its development

Deprenyl   effects during smoking and short-term abstinence

Deprenyl   facilitates recovery after stroke